Thermotherapy of Buruli Ulcer at Community Level, Cameroon

 

 

 

Treatment of the neglected tropical skin disease Buruli Ulcer (BU) relies currently on a single drug, rifampicin, which is given in combination with streptomycin. Development of an alternative treatment modality for patients suffering from severe side effects of the antibiotic treatment and in...

Ongoing
01.01.2018 - 31.03.2020
Clinical Trial
Medicor Foundation, Lichtenstein
Molecular Immunology
Gerd Pluschke
Preclinical profiling of virosomally formulated B-cell epitope mimetics derived from the novel key malaria vaccine candidates CyRPA and RH5

Clinical testing of two components for a synthetic peptide-based virosomal malaria vaccine has yielded promising results, encouraging the search for additional components for inclusion in a final multivalent vaccine formulation. This CTI project should support design, optimisation and final...

Ongoing
01.09.2015 - 31.08.2017
Research project
Commission for Technology and Innovation (CTI)
Molecular Immunology
Marco Tamborrini
LPEP - Surveillance to Evaluate the Approach and Impact of Leprosy Post-Exposure Prophylaxis

Leprosy is an infectious disease caused by Mycobacterium leprae. After an incubation period that can last years, the disease mainly affects peripheral nerves and the skin. If untreated, it may lead to loss of sensation and result in serious disabilities. The reported number of new leprosy patients...

Ongoing
01.12.2014 - 31.12.2019
Long term service project
Health Systems Support
Peter Steinmann
MuLeVaClin - Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis

Leishmaniasis was declared at the 60th WHO Assembly (2007) one of the world’s most neglected diseases. Leishmaniasis affects largely the poorest of the poor, mainly in developing countries as India, Bangladesh, Sudan, Ethiopia and Latin America. Existing treatments have severe drawbacks: side...

Ongoing
01.11.2013 - 30.09.2018
Clinical Trial
Molecular Immunology, Clinical Operations
Gerd Pluschke , Christian Burri , Marco Tamborrini
15.01.2006 - 15.12.2008
Clinical Trial
Molecular Immunology
Gerd Pluschke